Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Other Accumulated Expenses (2021 - 2025)

Aligos Therapeutics' Other Accumulated Expenses history spans 5 years, with the latest figure at $1.2 million for Q4 2025.

  • For Q4 2025, Other Accumulated Expenses fell 41.04% year-over-year to $1.2 million; the TTM value through Dec 2025 reached $1.2 million, down 41.04%, while the annual FY2025 figure was $1.2 million, 41.04% down from the prior year.
  • Other Accumulated Expenses reached $1.2 million in Q4 2025 per ALGS's latest filing, down from $4.8 million in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $4.8 million in Q3 2025 to a low of $483000.0 in Q2 2021.
  • Average Other Accumulated Expenses over 5 years is $2.0 million, with a median of $1.5 million recorded in 2022.
  • Peak YoY movement for Other Accumulated Expenses: soared 118.19% in 2024, then tumbled 41.04% in 2025.
  • A 5-year view of Other Accumulated Expenses shows it stood at $1.2 million in 2021, then increased by 19.27% to $1.5 million in 2022, then skyrocketed by 105.36% to $3.0 million in 2023, then crashed by 32.5% to $2.0 million in 2024, then crashed by 41.04% to $1.2 million in 2025.
  • Per Business Quant, the three most recent readings for ALGS's Other Accumulated Expenses are $1.2 million (Q4 2025), $4.8 million (Q3 2025), and $3.8 million (Q2 2025).